# Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

> **NCT03280056** · PHASE3 · COMPLETED · sponsor: **Brainstorm-Cell Therapeutics** · enrollment: 196 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **BIOLOGICAL:** NurOwn® (MSC-NTF cells)
- **OTHER:** Placebo
- **OTHER:** Bone Marrow aspiration

## Key facts

- **NCT ID:** NCT03280056
- **Lead sponsor:** Brainstorm-Cell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-28
- **Primary completion:** 2020-09-29
- **Final completion:** 2020-09-29
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03280056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03280056, "Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03280056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*